A5104667298- Liver Disease and Transplantation
- Organ Transplantation Techniques and Outcomes
- Electrolyte and hormonal disorders
University of Pennsylvania
2023-2024
Hepatorenal syndrome-acute kidney injury (HRS-AKI) is associated with significant morbidity and mortality. While liver transplantation the definitive treatment, continuous terlipressin infusion for HRS-AKI may provide benefit and, as such, was assessed in a population composed of candidates transplant (LT). Fifty hospitalized LT-eligible patients received single bolus followed by infusion. Acute-on-chronic failure grade 3, serum creatinine (SCr)>5.0 mg/dL, or Model End-Stage Liver Disease...
Hepatorenal syndrome-acute kidney injury (HRS-AKI) carries significant morbidity and mortality among those with end-stage liver disease. Bolus terlipressin for treatment of HRS-AKI received FDA approval in September 2022. US implementation terlipressin, however, is hindered by the paucity local data on optimal patient population administration mode, as well effect transplant priority. The INFUSE study designed to evaluate use continuous infusion candidates advanced disease HRS-AKI. Fifty...